Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117749292 | 11774929 | 2 | F | 20150922 | 20160627 | 20151124 | 20160701 | EXP | US-JAZZ-2015-US-018799 | JAZZ | 42.02 | YR | F | Y | 0.00000 | 20160701 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 117749292 | 11774929 | 1 | PS | XYREM | SODIUM OXYBATE | 1 | Oral | 1.5 G, BID | U | 21196 | 1.5 | G | ORAL SOLUTION | ||||||
| 117749292 | 11774929 | 2 | SS | XYREM | SODIUM OXYBATE | 1 | Oral | DOSE ADJUSTMENTS | U | 21196 | ORAL SOLUTION | ||||||||
| 117749292 | 11774929 | 3 | SS | XYREM | SODIUM OXYBATE | 1 | Oral | 4.5 G, BID | U | 21196 | 4.5 | G | ORAL SOLUTION | ||||||
| 117749292 | 11774929 | 4 | C | LINZESS | LINACLOTIDE | 1 | UNK | U | 0 | CAPSULE | |||||||||
| 117749292 | 11774929 | 5 | C | DICYCLOMINE | DICYCLOMINE HYDROCHLORIDE | 1 | UNK | U | 0 | CAPSULE | |||||||||
| 117749292 | 11774929 | 6 | C | MIRENA | LEVONORGESTREL | 1 | UNK | U | 0 | ||||||||||
| 117749292 | 11774929 | 7 | C | NASCOBAL | CYANOCOBALAMIN | 1 | UNK | U | 0 | NASAL SPRAY | |||||||||
| 117749292 | 11774929 | 8 | C | GABAPENTIN. | GABAPENTIN | 1 | UNK | U | 0 | CAPSULE | |||||||||
| 117749292 | 11774929 | 9 | C | VENTOLIN HFA | ALBUTEROL SULFATE | 1 | UNK | U | 0 | INHALER | |||||||||
| 117749292 | 11774929 | 10 | C | SINGULAIR | MONTELUKAST SODIUM | 1 | UNK | U | 0 | TABLET | |||||||||
| 117749292 | 11774929 | 11 | C | EFFEXOR XR | VENLAFAXINE HYDROCHLORIDE | 1 | UNK | U | 0 | CAPSULE |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 117749292 | 11774929 | 1 | Narcolepsy |
| 117749292 | 11774929 | 4 | Product used for unknown indication |
| 117749292 | 11774929 | 5 | Product used for unknown indication |
| 117749292 | 11774929 | 6 | Product used for unknown indication |
| 117749292 | 11774929 | 7 | Product used for unknown indication |
| 117749292 | 11774929 | 8 | Product used for unknown indication |
| 117749292 | 11774929 | 9 | Product used for unknown indication |
| 117749292 | 11774929 | 10 | Product used for unknown indication |
| 117749292 | 11774929 | 11 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 117749292 | 11774929 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 117749292 | 11774929 | Headache | |
| 117749292 | 11774929 | Sleep apnoea syndrome | |
| 117749292 | 11774929 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 117749292 | 11774929 | 1 | 201410 | 201412 | 0 | |
| 117749292 | 11774929 | 2 | 201412 | 201509 | 0 | |
| 117749292 | 11774929 | 3 | 201509 | 0 | ||
| 117749292 | 11774929 | 4 | 20151102 | 20151104 | 0 | |
| 117749292 | 11774929 | 5 | 20150826 | 0 | ||
| 117749292 | 11774929 | 6 | 20150826 | 0 | ||
| 117749292 | 11774929 | 7 | 20141006 | 20151103 | 0 | |
| 117749292 | 11774929 | 8 | 20140709 | 0 | ||
| 117749292 | 11774929 | 9 | 20130909 | 0 | ||
| 117749292 | 11774929 | 10 | 20120909 | 0 | ||
| 117749292 | 11774929 | 11 | 20090909 | 0 |